The ROI of Rapid Diagnostics: Can a 10-Minute Test Actually Save You Money?

Every unnecessary antibiotic prescription costs more than the price of the medication itself.

It can lead to repeat visits, adverse drug reactions, unnecessary laboratory testing, lower patient satisfaction when symptoms persist, and mounting pressure on antibiotic stewardship programs. Add clinician time, overcrowded waiting rooms, and declining reimbursement margins, and the financial impact becomes much larger than most healthcare organizations realize.

Urgent care centers and emergency departments face this challenge every day. A patient walks in with fever, sore throat, cough, and body aches. Is it viral? Is it bacterial? The symptoms overlap, and the answer isn’t always obvious during a brief clinical encounter.

This is exactly where rapid host-response diagnostics are beginning to reshape both clinical care and financial performance.

The Hidden Cost of Diagnostic Uncertainty

Respiratory infections account for millions of outpatient and urgent care visits every year. While many are viral, clinicians often face significant diagnostic uncertainty during the initial evaluation.

The consequences extend well beyond the exam room.

A single uncertain diagnosis can trigger:

• Unnecessary antibiotic prescribing
• Additional laboratory workups
• Repeat patient visits
• Delayed clinical decisions
• Longer room occupancy
• Increased clinician cognitive burden
• Lower patient confidence when treatment plans feel uncertain

None of these line items may seem substantial individually. Together, they represent a significant operational expense.

Healthcare leaders increasingly recognize that uncertainty itself has a measurable cost.

Fast Answers Create Operational Efficiency

Healthcare administrators often evaluate new technology based on acquisition cost.

A better question is:

What does it cost to keep operating without it?

Every additional 20 or 30 minutes spent waiting for diagnostic clarity slows patient flow.

Multiply that delay across dozens of respiratory patients during influenza season.

The numbers become meaningful.

When clinicians receive clinically actionable information during the same patient encounter, several downstream processes become more efficient:

• Treatment decisions happen sooner.
• Discharge instructions become more specific.
• Patients spend less time occupying examination rooms.
• Staff spend less time answering follow-up questions.
• Providers experience fewer “just-in-case” prescribing decisions.

Improving throughput doesn’t necessarily require hiring additional staff. Sometimes it simply requires reducing uncertainty.

Why Traditional Testing Doesn’t Always Solve the Problem

Many respiratory diagnostic tests are designed to identify a specific pathogen.

That approach certainly has value.

But respiratory illness isn’t always caused by the pathogens included on a testing panel, and identifying a virus doesn’t automatically exclude bacterial co-infection. Conversely, failing to detect a pathogen doesn’t necessarily explain why the patient is ill.

Clinicians still have to answer the question that matters most:

Does this patient likely have a bacterial infection requiring antibiotics?

That clinical decision often depends less on detecting the pathogen itself and more on understanding how the patient’s immune system is responding.

Host Response Testing Offers a Different Perspective

Instead of searching directly for bacteria or viruses, FebriDx® evaluates the body’s immune response.

Using a simple fingerstick blood sample, the test simultaneously measures two clinically relevant biomarkers:

• Myxovirus resistance protein A (MxA), a protein produced in response to viral infections through interferon signaling
• C-reactive protein (CRP), an acute-phase inflammatory marker that may rise during bacterial infections and other inflammatory conditions

Together, these biomarkers provide clinicians with additional evidence that helps differentiate between bacterial acute respiratory infection from non-bacterial etiology.

The distinction is important.

Rather than asking, “Which pathogen is present?”, clinicians gain insight into “How is the immune system responding?”

That information often aligns more closely with real-world prescribing decisions.

Ten Minutes Can Change the Entire Visit

Clinical workflow rarely improves because of one dramatic innovation.

More often, it improves through small reductions in friction.

Imagine a busy urgent care clinic on a Monday morning.

A 34-year-old teacher presents with fever, sore throat, congestion, fatigue, and a persistent cough. Symptoms began two days ago. Physical examination doesn’t clearly indicate bacterial disease. The patient expects antibiotics because they “always help.”

Without additional diagnostic information, the clinician faces an uncomfortable choice:

Prescribe antibiotics despite uncertainty.

Or decline antibiotics and risk patient dissatisfaction.

Now imagine the same encounter with a point-of-care host-response result available in approximately 10 minutes while the patient remains in the examination room.

The conversation changes.

Treatment recommendations become more evidence-based.

Patient education becomes easier.

The clinician has objective data to support the decision.

The visit moves forward with greater confidence.

Antibiotic Stewardship Is Also Financial Stewardship

Antimicrobial resistance isn’t just a public health issue.

It’s becoming a financial one.

Healthcare organizations continue investing significant resources into antimicrobial stewardship initiatives, quality reporting, clinician education, and prescribing oversight.

Reducing inappropriate antibiotic use helps support:

• Stewardship program goals
• Quality improvement initiatives
• Reduced medication-related adverse events
• Better alignment with evidence-based care
• Improved patient trust through transparent clinical decision-making

Rapid host-response diagnostics provide another tool clinicians can use when prescribing decisions aren’t immediately clear.

The result isn’t simply fewer antibiotics.

It’s greater prescribing confidence.

Looking Beyond the Price Per Test

Procurement teams naturally compare unit costs.

That makes sense.

But the true return on investment often comes from downstream savings rather than the purchase price alone.

When evaluating rapid diagnostics, decision-makers should ask broader questions.

Does the test help reduce unnecessary antibiotic prescribing?

Can it shorten patient visits?

Will it improve clinician confidence?

Does it support antimicrobial stewardship metrics?

Could it reduce repeat visits caused by diagnostic uncertainty?

Will it improve operational efficiency during the respiratory virus season?

A diagnostic test should not be viewed solely as a laboratory expense.

It should be evaluated as a workflow improvement tool.

Measuring ROI Where It Actually Happens

The financial impact of rapid diagnostics extends across multiple departments.

Clinical Operations
Faster decision-making can improve patient throughput while reducing bottlenecks during seasonal surges.

Provider Productivity
Clinicians spend less time debating borderline prescribing decisions and documenting clinical uncertainty.

Patient Experience
Patients receive answers before leaving the clinic rather than waiting for additional testing or empirical treatment.

Healthcare Economics
Avoiding unnecessary prescriptions, follow-up appointments, and additional diagnostic workups may produce meaningful operational savings over time.

These improvements don’t always appear on the same budget sheet.

That doesn’t make them any less real.

Why FebriDx Fits Modern Point-of-Care Workflows

FebriDx was developed for environments where clinicians need rapid, actionable information without disrupting workflow.

Its practical advantages include:

• Fingerstick whole blood sample
• Host immune response assessment using MxA and CRP
• Differentiation of bacterial versus viral acute respiratory infections
• Results available in approximately 10 minutes
• Designed for point-of-care use during the patient visit

For urgent care centers, emergency departments, primary care practices, and other outpatient settings, that combination supports faster clinical decisions while complementing existing diagnostic pathways rather than replacing clinical judgment.

The Bottom Line

The question isn’t whether a rapid diagnostic test has a purchase price.

Every diagnostic tool does.

The better question is what diagnostic uncertainty is already costing your organization—in unnecessary antibiotic prescriptions, longer patient visits, workflow inefficiencies, repeat encounters, and clinician frustration.

When a point-of-care test delivers clinically relevant information in about 10 minutes, the return on investment often extends far beyond the laboratory budget.

Sometimes the most valuable savings aren’t generated by doing less.

They’re created by knowing more—earlier.

Why Providers Choose Dx Direct

For clinics interested in implementing FebriDx, Dx Direct provides a streamlined and reliable path to adoption. As a direct distribution partner aligned with Lumos Diagnostics, Dx Direct offers an authorized supply chain, focused product expertise, and dedicated support tailored specifically to FebriDx. Providers benefit from simplified ordering, flexible subscription and volume-based purchasing options, onboarding assistance, clinical education resources, and reimbursement support—making it easier to integrate rapid diagnostic testing into everyday practice.